Endothelial Dysfunction, Biomarkers, and Lung Function -Ancillary to MESA
This trial is active, not recruiting.
|Conditions||chronic obstructive pulmonary disease (copd), emphysema, endothelial dysfunction|
|Collaborator||National Heart, Lung, and Blood Institute (NHLBI)|
|Start date||October 2004|
|End date||November 2012|
|Trial size||4359 participants|
|Trial identifier||NCT00843271, AAAA7791, NCT00094224, R01HL077612|
The purpose of MESA-Lung is to assess the role of endothelial dysfunction and genetic susceptibility in subclinical COPD.
time frame: 2004-2011
time frame: 2000-2011
Male or female participants from 45 years up to 84 years old.
Inclusion Criteria: - A random sample of MESA participants active at Exam 3 and/or 4. Exclusion Criteria: - MESA participants without MESA Exam 3 or 4 measurements. - MESA participants without FMD measurements in Exam 1. - MESA participants who have not consented to genetic testing.
|Official title||Endothelial Dysfunction, Biomarkers, and Lung Function (MESA LUNG)|
|Principal investigator||R. Graham Barr, M.D., Dr.PH.|
|Description||Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death in the United States, and morbidity and mortality from COPD continue to rise. Despite the magnitude of the problem, therapeutic options are limited - particularly in comparison to cardiovascular disease. Smoking cessation is essential to the treatment and prevention of COPD. However, although smoking is the principal cause of COPD, only a minority of smokers develops symptomatic COPD and many former smokers develop COPD years to decades after they have stopped smoking. The only other medical intervention proven to reduce mortality from COPD is supplemental oxygen therapy. There is therefore an urgent need for newer understandings of the pathophysiology of COPD that might lead to the development of better therapies for COPD. MESA-Lung is ancillary of the ongoing Multi-Ethnic Study of Atherosclerosis (MESA). MESA-lung will utilize the various existing measures of endothelial function that have been already been collected in MESA (flow-mediated dilatation [FMD] and related biomarkers and gene polymorphisms) to test the hypotheses that the endothelial dysfunction occurs in the clinical COPD.|
Call for more information